Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing ...

“In people who have diabetes, when they’re on GLP-1s, they experience an early increase in the risk of diabetic retinopathy,” ...

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of ...

A large propensity-matched retrospective cohort study showed a small but statistically significant 7% increase in new-onset ...

Credit: Shutterstock. Tarcocimab tedromer is an investigational VEGF inhibitor designed to improve bioavailability and intraocular half-life using the Company’s antibody biopolymer conjugate platform.

Eyepoint Pharma ( ($EYPT) ) has released its Q3 earnings. Here is a breakdown of the information Eyepoint Pharma presented to its investors.

The MarketWatch News Department was not involved in the creation of this content. Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...